Drugs / Seviteronel
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04947189 | Nov 2022 → Jul 2026 overdue | triple-negative breast carcinoma | St Vincent's Hospital, Sydney | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02580448 | Aug 2015 → Jan 2019 | estrogen-receptor positive breast cancer, male breast carcinoma, triple-negative breast carcinoma | Innocrin Pharmaceutical | Completed | No outcome recorded |
| Phase 1/2 | NCT02361086 | Jun 2014 → Dec 2017 | castration-resistant prostate carcinoma | Innocrin Pharmaceutical | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03600467 | Aug 2018 → Feb 2021 | cancer | St Vincent's Hospital, Sydney | Terminated | No outcome recorded |
| Phase 2 | NCT02445976 | May 2015 → Dec 2018 | prostate cancer | Innocrin Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT02130700 | Apr 2014 → Sep 2017 | prostate cancer | Innocrin Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT02012920 | Dec 2011 → Dec 2018 | castration-resistant prostate carcinoma | Innocrin Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seviteronel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04947189 ↗ |
| Known as | VT-464 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02361086 ↗ |
| Action | Inhibit | “a lyase-selective inhibitor of CYP17” NCT02012920 ↗1“Cytochrome P450 17A1 inhibitor” CHEMBL3264610 ↗ |
| Modality | Small molecule | — CHEMBL3264610 ↗ |
| Route | Oral | “Seviteronel: given orally once daily in 28 day cycles” NCT02012920 ↗ |
| Target | AR | “Seviteronel inhibits the AR through competitive antagonism of both wild-type and mutated forms of the receptor.” NCT04947189 ↗ |
| Target | CYP17A1 | “Cytochrome P450 17A1 inhibitor” CHEMBL3264610 ↗ |